GKOS
Glaukos Corp Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$237.60Close
$13.7BMarket cap
$81.79 – $242.4852-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 98 · stronger than 98% of stocks over 12 months
- Near its high 2% below its 52-week high
Cautions
- Extended 7.8 ATR above its 50-day average
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
2%
1wk
up 32.8%
price change
1mo
up 44.7%
price change
12-month return
up 171%
market up 11% ·
its own up 197%
F-score
3 / 9
Weak
Altman Z
33.42
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
20.8×
price / book
Earnings yield
down 1.5%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
up 32%
year on year
EPS growth
—
latest quarter
Sales growth
up 58%
latest quarter · +8 pts
ROE
down 26%
return on equity
Free cash margin
down 4%
-$22.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profits backed by cash
- reduced long-term debt
- assets working harder
Trade setup
ATR%
4.8%
$11.32 a day · 2×ATR $214.97
RS
98 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
2.1×
vs 50-day average
Up/down volume
1.25
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Gross margin narrowing Gross margin fell from 75.5% to 55.7%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Oct 28, 2026
Results reaction
Oct 28, 2026+34% vs market2 sessions after results
Financials
- Gross 56%
- Net -37%
- Free cash -4%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $225.0M | $294.0M | $282.9M | $314.7M | $383.5M | $507.4M |
| Gross margin | 59% | 77% | 76% | 76% | 75% | 56% |
| Operating income | -$123.6M | -$32.9M | -$82.3M | -$128.7M | -$122.4M | -$199.6M |
| Net income | -$120.3M | -$49.6M | -$99.2M | -$134.7M | -$146.4M | -$187.7M |
| Net margin | -53% | -17% | -35% | -43% | -38% | -37% |
| Earnings per share | -$2.70 | -$1.07 | -$2.09 | -$2.78 | -$2.77 | -$3.28 |
| Free cash flow | -$29.9M | -$23.1M | -$63.3M | -$78.0M | -$67.6M | -$22.5M |
| Free cash margin | -13% | -8% | -22% | -25% | -18% | -4% |
| Cash | $96.6M | $100.7M | $119.5M | $93.5M | $169.6M | $90.8M |
| Shareholders' equity | $667.4M | $587.2M | $530.0M | $461.8M | $766.9M | $656.2M |
| Shares outstanding | 45.25m | 46.97m | 47.75m | 49.12m | 56.44m | 57.51m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 28, 2026 | Quarterly ↗ | Sep 30, 2026 | 28d |
| Jul 29, 2026 | Quarterly ↗ | Jun 30, 2026 | 29d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 23, 2026 | Annual ↗ | Dec 31, 2025 | 54d |
| Oct 31, 2025 | Quarterly ↗ | Sep 30, 2025 | 31d |
| Aug 4, 2025 | Quarterly ↗ | Jun 30, 2025 | 35d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 2, 2024 | Quarterly ↗ | Jun 30, 2024 | 33d |
| May 3, 2024 | Quarterly ↗ | Mar 31, 2024 | 33d |
| Feb 23, 2024 | Annual ↗ | Dec 31, 2023 | 54d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Results · Regulation FD ↗ |
| Aug 3, 2026 | Regulation FD ↗ |
| Jul 29, 2026 | Results · Regulation FD ↗ |
| Jun 3, 2026 | Shareholder vote ↗ |
| May 4, 2026 | Regulation FD ↗ |
| Apr 29, 2026 | Results · Regulation FD ↗ |
| Mar 2, 2026 | Regulation FD ↗ |
| Feb 17, 2026 | Results · Regulation FD ↗ |
| Jan 13, 2026 | Results · Regulation FD ↗ |
| Nov 10, 2025 | Regulation FD ↗ |
| Oct 29, 2025 | Results · Regulation FD ↗ |
| Aug 12, 2025 | Regulation FD ↗ |